Physician profile
Maureen Watts
NPI 1750497434
$47,907.29
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $16K · 2021: $7,717 · 2022: $15K · 2023: $8,118 · 2024: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,463 · Food and Beverage: $1,543 · Travel and Lodging: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,462.50 |
| Food and Beverage | $1,542.78 |
| Travel and Lodging | $400.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,969.49 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $15,427.71 | 2019-2021 | |
| Lilly USA, LLC | $814.64 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $517.84 | 2019-2022 | |
| Amgen INC. | $447.78 | 2019-2023 | Aimovig |
| Lundbeck LLC | $416.98 | 2020-2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $339.20 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $312.51 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $270.17 | 2022 | |
| Pfizer INC. | $246.45 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $188.82 | 2022-2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $127.89 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $93.73 | 2019-2020 | |
| Ucb, INC. | $93.10 | 2019 | |
| Currax Pharmaceuticals LLC | $84.86 | 2019-2023 | Onzetra Xsail |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $72.72 | 2021 | |
| Scilex Pharmaceuticals INC. | $72.55 | 2023-2024 | Ztlido |
| Assertio Therapeutics, INC. | $60.30 | 2019-2020 | |
| Grifols USA, LLC | $60.03 | 2019-2020 | |
| Merz North America, INC. | $41.08 | 2019 | |
| Amneal Pharmaceuticals LLC | $39.28 | 2020-2021 | |
| Promius Pharma LLC | $38.85 | 2019 | |
| Aquestive Therapeutics, INC. | $37.36 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.93 | 2022 | |
| Bausch Health US, LLC | $22.59 | 2019 | |
| Sk Life Science, INC. | $22.10 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.69 | 2023 | Dysport |
| Greenwich Biosciences, INC. | $18.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.